Literature DB >> 8157270

Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif.

I Tarpey1, S Stacey, J Hickling, H D Birley, A Renton, A McIndoe, D H Davies.   

Abstract

Cytotoxic T lymphocytes (CTL) may play an important role in the control of human papillomavirus (HPV)-induced anogenital neoplasias, but have been difficult to study owing to the difficulty in obtaining sufficient quantities of infectious virus. To address this we have stimulated human HPV-specific CTL in vitro using low-density cells (LDC) from peripheral blood mononuclear cells (PBMC). Low-density cells were used to present synthetic peptides, or endogenously processed peptides expressed from recombinant vaccinia viruses, to high-density PBMC (predominantly lymphocytes) for 6 days. Cytotoxic T lymphocytes stimulated with endogenously processed HPV 11 E7 recognized the synthetic HLA-A2 (A*0201) motif-containing nonamer, 4-12. In reciprocal experiments, CTL stimulated with this peptide in vitro recognized targets expressing endogenously processed E7. The responses in each case were A2 restricted and peptide specific. Two additional A2 motif-containing nonamers from HPV 6b E7 (21-30 and 47-55) also elicited peptide-specific, A2-restricted CTL. The data illustrate the potential that in vitro stimulation with LDC has in understanding CTL responses to experimentally problematic viral systems such as HPV, and may offer a route to specific immunotherapy of HPV-associated lesions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157270      PMCID: PMC1422317     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Prediction of an HLA B8-restricted influenza epitope by motif.

Authors:  A Suhrbier; C Schmidt; A Fernan
Journal:  Immunology       Date:  1993-05       Impact factor: 7.397

2.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex.

Authors:  V Cerundolo; J Alexander; K Anderson; C Lamb; P Cresswell; A McMichael; F Gotch; A Townsend
Journal:  Nature       Date:  1990-05-31       Impact factor: 49.962

Review 3.  Heterogeneity of the human papillomavirus group.

Authors:  E M de Villiers
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

4.  The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes.

Authors:  K Münger; W C Phelps; V Bubb; P M Howley; R Schlegel
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

5.  Papillomaviruses in human cancers.

Authors:  H Zur Hausen
Journal:  Mol Carcinog       Date:  1988       Impact factor: 4.784

6.  Human papilloma virus DNA: physical mapping and genetic heterogeneity.

Authors:  L Gissmann; H zur Hausen
Journal:  Proc Natl Acad Sci U S A       Date:  1976-04       Impact factor: 11.205

7.  Laboratory production in vivo of infectious human papillomavirus type 11.

Authors:  J W Kreider; M K Howett; A E Leure-Dupree; R J Zaino; J A Weber
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

8.  The nucleotide sequence and genome organization of human papilloma virus type 11.

Authors:  K Dartmann; E Schwarz; L Gissmann; H zur Hausen
Journal:  Virology       Date:  1986-05       Impact factor: 3.616

Review 9.  Human papillomaviruses and carcinomas.

Authors:  D A Galloway; J K McDougall
Journal:  Adv Virus Res       Date:  1989       Impact factor: 9.937

10.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes.

Authors:  A Schneider-Gädicke; E Schwarz
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

View more
  8 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.

Authors:  Shiwen Peng; Austin Mattox; Simon R Best; Anca M Barbu; James A Burns; Belinda Akpeng; Jessica Jeang; Benjamin Yang; Eiichi Ishida; Chien-Fu Hung; Tzyy-Choou Wu; Sara I Pai
Journal:  Cancer Immunol Immunother       Date:  2016-01-13       Impact factor: 6.968

Review 3.  Peptide binding to MHC class I molecules: implications for antigenic peptide prediction.

Authors:  K C Parker; M Shields; M DiBrino; A Brooks; J E Coligan
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

Review 4.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

5.  The use of bovine MHC class I allele-specific peptide motifs and proteolytic cleavage specificities for the prediction of potential cytotoxic T lymphocyte epitopes of bovine viral diarrhea virus.

Authors:  N R Hegde; S Srikumaran
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

6.  Prediction of potential cytotoxic T lymphocyte epitopes of bovine herpesvirus 1 based on allele-specific peptide motifs and proteolytic cleavage specificities.

Authors:  N R Hegde; S Srikumaran
Journal:  Virus Genes       Date:  1996       Impact factor: 2.332

7.  Isolation and characterization of human papillomavirus type 6-specific T cells infiltrating genital warts.

Authors:  K Hong; C E Greer; N Ketter; G Van Nest; X Paliard
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

8.  Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.

Authors:  Riyasat Ali; Jeffrey Babad; Antonia Follenzi; John A Gebe; Michael A Brehm; Gerald T Nepom; Leonard D Shultz; Dale L Greiner; Teresa P DiLorenzo
Journal:  Immunology       Date:  2016-08       Impact factor: 7.397

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.